Physician

Meera Shreedhara Vasudha, MD

According to 2025 Medicare claims, Meera Vasudha, MD (NPI: 1639388689) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Hunt, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75401-7852. Vasudha is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Vasudha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 617 traditional Medicare patients, billed 219,483 HCPCS/CPT codes, and received $2,514,711 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,695 prescription claims across 349 beneficiaries totaling $2,938,191 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 10 records totaling $251. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,026,383 to $2,938,191. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	778	214,844	$2,074,553
2016	823	257,915	$2,110,666
2017	718	190,061	$1,826,191
2018	723	198,619	$1,882,633
2019	745	206,657	$2,607,514
2020	712	187,954	$2,646,109
2021	685	187,243	$2,175,473
2022	673	195,430	$2,147,427
2023	687	223,921	$2,112,346
2024	617	219,483	$2,514,711

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	237	1,237	$1,026,383
2016	245	1,459	$1,136,738
2017	233	1,553	$990,368
2018	263	1,590	$1,362,777
2019	279	1,574	$2,140,820
2020	297	1,697	$2,469,007
2021	271	1,423	$1,673,303
2022	290	1,647	$2,379,514
2023	341	1,767	$2,446,490
2024	349	1,695	$2,938,191

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	28	177	$85,396
2016	36	173	$74,732
2017	N/R	36	$7,794
2018	N/R	83	$9,768
2019	N/R	49	$5,528
2020	N/R	N/R	N/R
2021	N/R	30	$2,350
2022	N/R	40	$1,410
2023	N/R	N/R	N/R
2024	N/R	12	$226

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	104	160	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	288	564	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	193	215	$57
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	85	193	$45
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	437	691	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	917	$587,258
Sprycel	Dasatinib	24	720	$321,526
Erleada	Apalutamide	22	660	$311,325
Brukinsa	Zanubrutinib	21	630	$309,408
Calquence	Acalabrutinib Maleate	18	540	$270,436

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$251	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Meera Shreedhara Vasudha, MD?

Tedicare shows public-source Medicare data for Meera Shreedhara Vasudha, MD (NPI 1639388689), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Meera Shreedhara Vasudha, MD have ACO affiliation data?

Meera Shreedhara Vasudha, MD is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Meera Shreedhara Vasudha, MD?

Meera Shreedhara Vasudha, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Meera Shreedhara Vasudha, MD have Open Payments data?

Meera Shreedhara Vasudha, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.